Cannabinoid Encyclopedia

How research is judged

What does Mechanistic evidence mean?

Evidence about plausible biological pathways, not proof of consumer benefit. 1

Also called: biochemical, mechanism, mechanistic, pharmacological

Simple definition

Mechanistic evidence, in plain English

Evidence about plausible biological pathways, not proof of consumer benefit. 1

Why it matters

How this word is used in cannabinoid research

This term tells you what kind of research you are reading. It helps separate stronger human evidence from early or indirect evidence.

How to read it

Use the term to understand the study, then open the source before drawing a conclusion.

Do not confuse this with

Common questions

Questions people ask

What does Mechanistic evidence mean?

Evidence about plausible biological pathways, not proof of consumer benefit.

Why does Mechanistic evidence matter?

This term tells you what kind of research you are reading. It helps separate stronger human evidence from early or indirect evidence.

Is Mechanistic evidence proof that a cannabinoid works?

No. A definition helps explain the language. The related research pages and their sources show what was actually studied.

Sources

Research connected to this term

Definitions explain the word. These links show research records currently connected with it.

  1. 1
    A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats mechanistic or pharmacological PubMed 39528623
  2. 2
    Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. mechanistic or pharmacological PubMed 41680865
  3. 3
    Cannabis Therapeutics and the Future of Neurology. mechanistic or pharmacological PubMed 30405366
  4. 4
    A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. mechanistic or pharmacological PubMed 30374683
  5. 5
    Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. mechanistic or pharmacological PubMed 37764262
  6. 6
    Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation. mechanistic or pharmacological PubMed 41256665
See all 325 connected research sources
  1. 1
    A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats mechanistic or pharmacological PubMed 39528623
  2. 2
    Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. mechanistic or pharmacological PubMed 41680865
  3. 3
    Cannabis Therapeutics and the Future of Neurology. mechanistic or pharmacological PubMed 30405366
  4. 4
    A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. mechanistic or pharmacological PubMed 30374683
  5. 5
    Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. mechanistic or pharmacological PubMed 37764262
  6. 6
    Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation. mechanistic or pharmacological PubMed 41256665
  7. 7
    Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation. mechanistic or pharmacological PubMed 42139799
  8. 8
    Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. mechanistic or pharmacological PubMed 27573936
  9. 9
    SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. mechanistic or pharmacological PubMed 42196303
  10. 10
    In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. mechanistic or pharmacological PubMed 33230154
  11. 11
    Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips. mechanistic or pharmacological PubMed 39968488
  12. 12
    The Impact of Major and Minor Phytocannabinoids on the Maintenance and Function of INS-1 β-Cells Under High-Glucose and High-Lipid Conditions. mechanistic or pharmacological PubMed 40363798
  13. 13
    Plasma cannabinoid concentrations and transference during long-term industrial hemp administration in cattle. mechanistic or pharmacological PubMed 41358942
  14. 14
    Effects of maternal edible THC consumption on offspring lung growth and function in a rhesus macaque model. mechanistic or pharmacological PubMed 39903192
  15. 15
    Cannabidivarin is anticonvulsant in mouse and rat. mechanistic or pharmacological PubMed 22970845
  16. 16
    Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. mechanistic or pharmacological PubMed 31447649
  17. 17
    Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans. mechanistic or pharmacological PubMed 36583706
  18. 18
    Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. mechanistic or pharmacological PubMed 29057454
  19. 19
    Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. mechanistic or pharmacological PubMed 32488349
  20. 20
    Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats. mechanistic or pharmacological PubMed 31897571
  21. 21
    Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. mechanistic or pharmacological PubMed 23121618
  22. 22
    A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. mechanistic or pharmacological PubMed 24595502
  23. 23
    Antiviral activities of hemp cannabinoids. mechanistic or pharmacological PubMed 37083031
  24. 24
    Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. mechanistic or pharmacological PubMed 30225659
  25. 25
    The effect of phytocannabinoids on airway hyper-responsiveness, airway inflammation, and cough. mechanistic or pharmacological PubMed 25655949
  26. 26
    Behavioural and molecular effects of cannabidiolic acid in mice. mechanistic or pharmacological PubMed 32798553
  27. 27
    Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. mechanistic or pharmacological PubMed 39596290
  28. 28
    Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. mechanistic or pharmacological PubMed 42163693
  29. 29
    Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. mechanistic or pharmacological PubMed 39004335
  30. 30
    Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. mechanistic or pharmacological PubMed 41822224
  31. 31
    Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα. mechanistic or pharmacological PubMed 31325449
  32. 32
    Oxa-adamantyl cannabinoids. mechanistic or pharmacological PubMed 33636308
  33. 33
    Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. mechanistic or pharmacological PubMed 27498155
  34. 34
    Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. mechanistic or pharmacological PubMed 25999668
  35. 35
    Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology. mechanistic or pharmacological PubMed 37458709
  36. 36
    Hexahydrocannabinol-induced rhabdomyolysis and acute kidney injury: a case report combining comprehensive toxicokinetic and metabolomic investigations. mechanistic or pharmacological PubMed 42106886
  37. 37
    Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. mechanistic or pharmacological PubMed 23924692
  38. 38
    Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: Exploration of other potential receptor targets. mechanistic or pharmacological PubMed 40432283
  39. 39
    Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. mechanistic or pharmacological PubMed 18755158
  40. 40
    Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids. mechanistic or pharmacological PubMed 16107637
  41. 41
    Mu Opioid Receptors Acutely Regulate Adenosine Signaling in Striatal Glutamate Afferents. mechanistic or pharmacological PubMed 35091505
  42. 42
    Activation of nicotinic receptors on GABAergic amacrine cells in the rabbit retina indirectly stimulates dopamine release. mechanistic or pharmacological PubMed 11347816
  43. 43
    Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations. mechanistic or pharmacological PubMed 40016352
  44. 44
    Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. mechanistic or pharmacological PubMed 35176443
  45. 45
    Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells. mechanistic or pharmacological PubMed 34607960
  46. 46
    Impact of Chronic Moderate Exercise on Immune Cells and Cytokine Levels in Rats: Focus on the Endocannabinergic Pathway. mechanistic or pharmacological PubMed 37962860
  47. 47
    Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy. mechanistic or pharmacological PubMed 39334169
  48. 48
    Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain. mechanistic or pharmacological PubMed 38162115
  49. 49
    Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. mechanistic or pharmacological PubMed 34980287
  50. 50
    Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. mechanistic or pharmacological PubMed 17965195
  51. 51
    Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression. mechanistic or pharmacological PubMed 40269679
  52. 52
    Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice. mechanistic or pharmacological PubMed 41092478
  53. 53
    Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression. mechanistic or pharmacological PubMed 39245706
  54. 54
    Cannabinoid treatment for autism: a proof-of-concept randomized trial. mechanistic or pharmacological PubMed 33536055
  55. 55
    Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model. mechanistic or pharmacological PubMed 31350927
  56. 56
    Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4. mechanistic or pharmacological PubMed 33629929
  57. 57
    Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. mechanistic or pharmacological PubMed 21175579
  58. 58
    Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. mechanistic or pharmacological PubMed 33022751
  59. 59
    Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip. mechanistic or pharmacological PubMed 40750820
  60. 60
    Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model. mechanistic or pharmacological PubMed 40774642
  61. 61
    Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development. mechanistic or pharmacological PubMed 39008349
  62. 62
    Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. mechanistic or pharmacological PubMed 29540584
  63. 63
    An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. mechanistic or pharmacological PubMed 30585986
  64. 64
    Acute administration of THC impairs spatial but not associative memory function in zebrafish. mechanistic or pharmacological PubMed 24639045
  65. 65
    Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish. mechanistic or pharmacological PubMed 36424484
  66. 66
    Affinity-Based Protein Profiling Reveals IDH2 as a Mitochondrial Target of Cannabinol in Receptor-Independent Neuroprotection. mechanistic or pharmacological PubMed 40388656
  67. 67
    Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules. mechanistic or pharmacological PubMed 36091813
  68. 68
    Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes. mechanistic or pharmacological PubMed 39275884
  69. 69
    Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. mechanistic or pharmacological PubMed 36228902
  70. 70
    Phytocannabinoids as anti-inflammatory agents: Synergistic effects when combined with Cannabis sativa L. matrices. mechanistic or pharmacological PubMed 41478536
  71. 71
    Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis. mechanistic or pharmacological PubMed 40580876
  72. 72
    Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons. mechanistic or pharmacological PubMed 40568800
  73. 73
    Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. mechanistic or pharmacological PubMed 19679411
  74. 74
    Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol. mechanistic or pharmacological PubMed 36796712
  75. 75
    Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities. mechanistic or pharmacological PubMed 40540228
  76. 76
    Could cannabigerol protect against neuroinflammation? Insights from an in vitro microglial study. mechanistic or pharmacological PubMed 41548647
  77. 77
    The impact of cannabigerol exposure on human endometrial stromal cells decidualization. mechanistic or pharmacological PubMed 42107483
  78. 78
    Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. mechanistic or pharmacological PubMed 36272108
  79. 79
    Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models. mechanistic or pharmacological PubMed 41934896
  80. 80
    Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. mechanistic or pharmacological PubMed 35246858
  81. 81
    Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. mechanistic or pharmacological PubMed 25269802
  82. 82
    Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis. mechanistic or pharmacological PubMed 40326034
  83. 83
    Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat. mechanistic or pharmacological PubMed 37305529
  84. 84
    Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models. mechanistic or pharmacological PubMed 41155621
  85. 85
    Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation. mechanistic or pharmacological PubMed 40706771
  86. 86
    Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. mechanistic or pharmacological PubMed 20002104
  87. 87
    Cannabigerol reverses mechanical allodynia through α2A-adrenergic modulation of thalamocortical signaling in chemotherapy-induced neuropathy. mechanistic or pharmacological PubMed 41435878
  88. 88
    Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. mechanistic or pharmacological PubMed 23415610
  89. 89
    Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. mechanistic or pharmacological PubMed 36615835
  90. 90
    Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation. mechanistic or pharmacological PubMed 40818359
  91. 91
    Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea. mechanistic or pharmacological PubMed 40725084
  92. 92
    Cannabigerol Reduces Lipid Peroxidation Influencing Oxidative Stress and Inflammation Signaling Pathways in Melanocytes Exposed to UVA Radiation. mechanistic or pharmacological PubMed 41914282
  93. 93
    Cannabigerol Exerts In Vivo and In Vitro Anti-Inflammatory Effects via Inhibition of the MAPK and NF-κB Pathways. mechanistic or pharmacological PubMed 41423277
  94. 94
    Cannabigerol Alleviates Liver Damage in Metabolic Dysfunction-Associated Steatohepatitis Female Mice via Inhibition of Transforming Growth Factor Beta 1. mechanistic or pharmacological PubMed 40362835
  95. 95
    Sphingolipid metabolism and insulin resistance - Does cannabigerol protect against experimental colitis induced by high-fat high-sucrose diet? mechanistic or pharmacological PubMed 41056638
  96. 96
    In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. mechanistic or pharmacological PubMed 35056807
  97. 97
    Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway. mechanistic or pharmacological PubMed 39851511
  98. 98
    Mannich-type modifications of (-)-cannabidiol and (-)-cannabigerol leading to new, bioactive derivatives. mechanistic or pharmacological PubMed 37949940
  99. 99
    Skin cells protection against UVA radiation - The comparison of various antioxidants and viability tests. mechanistic or pharmacological PubMed 39647320
  100. 100
    The Anti-Inflammatory Action of Cannabigerol Accompanied by the Antioxidant Effect of 3-O-ethyl Ascorbic Acid in UVA-Irradiated Human Keratinocytes. mechanistic or pharmacological PubMed 37652708
  101. 101
    A new cannabigerol derivative, LE-127/2, induces autophagy mediated cell death in human cutaneous melanoma cells. mechanistic or pharmacological PubMed 39357769
  102. 102
    Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. mechanistic or pharmacological PubMed 27094344
  103. 103
    Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamus. mechanistic or pharmacological PubMed 31941059
  104. 104
    Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. mechanistic or pharmacological PubMed 22543671
  105. 105
    Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. mechanistic or pharmacological PubMed 33134364
  106. 106
    Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. mechanistic or pharmacological PubMed 20619971
  107. 107
    Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots. mechanistic or pharmacological PubMed 41668212
  108. 108
    In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. mechanistic or pharmacological PubMed 35306000
  109. 109
    Cannabichromene is a cannabinoid CB2 receptor agonist. mechanistic or pharmacological PubMed 31368508
  110. 110
    Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy. mechanistic or pharmacological PubMed 40790027
  111. 111
    Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene. mechanistic or pharmacological PubMed 39137108
  112. 112
    The Oxidation of Phytocannabinoids to Cannabinoquinoids. mechanistic or pharmacological PubMed 32315173
  113. 113
    Structure and Dynamics of Cannabinoid Binding to the GABAA Receptor. mechanistic or pharmacological PubMed 40271542
  114. 114
    The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. mechanistic or pharmacological PubMed 23373571
  115. 115
    Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. mechanistic or pharmacological PubMed 22300105
  116. 116
    In silico discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery. mechanistic or pharmacological PubMed 35399958
  117. 117
    Cannabichromene attenuates fracture pain but impairs bone repair in a murine tibial fracture model. mechanistic or pharmacological PubMed 41794091
  118. 118
    Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity. mechanistic or pharmacological PubMed 41322279
  119. 119
    Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain. mechanistic or pharmacological PubMed 36551296
  120. 120
    Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. mechanistic or pharmacological PubMed 20942863
  121. 121
    Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. mechanistic or pharmacological PubMed 39769302
  122. 122
    Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. mechanistic or pharmacological PubMed 35628241
  123. 123
    Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties. mechanistic or pharmacological PubMed 37242431
  124. 124
    Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway. mechanistic or pharmacological PubMed 36769042
  125. 125
    Cannabichromene Induces Neuronal Differentiation in NSC-34 Cells: Insights from Transcriptomic Analysis. mechanistic or pharmacological PubMed 36983897
  126. 126
    Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations. mechanistic or pharmacological PubMed 40358684
  127. 127
    The effect of cannabichromene on adult neural stem/progenitor cells. mechanistic or pharmacological PubMed 23941747
  128. 128
    Tetrahydrocannabivarin (THCV) Protects Adipose-Derived Mesenchymal Stem Cells (ASC) against Endoplasmic Reticulum Stress Development and Reduces Inflammation during Adipogenesis. mechanistic or pharmacological PubMed 37108282
  129. 129
    High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain. mechanistic or pharmacological PubMed 32904155
  130. 130
    Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption. mechanistic or pharmacological PubMed 41947574
  131. 131
    The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. mechanistic or pharmacological PubMed 26577065
  132. 132
    Hair Regrowth with Novel Hemp Extract: A Case Series. mechanistic or pharmacological PubMed 37305187
  133. 133
    The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. mechanistic or pharmacological PubMed 23712280
  134. 134
    Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. mechanistic or pharmacological PubMed 16205722
  135. 135
    Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats. mechanistic or pharmacological PubMed 41008636
  136. 136
    Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6. mechanistic or pharmacological PubMed 30170189
  137. 137
    Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. mechanistic or pharmacological PubMed 31454413
  138. 138
    The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. mechanistic or pharmacological PubMed 20590571
  139. 139
    The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. mechanistic or pharmacological PubMed 17245367
  140. 140
    Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. mechanistic or pharmacological PubMed 23902479
  141. 141
    The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. mechanistic or pharmacological PubMed 18311186
  142. 142
    Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. mechanistic or pharmacological PubMed 25542687
  143. 143
    TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site. mechanistic or pharmacological PubMed 38691614
  144. 144
    Loratadine, an antihistaminic drug, suppresses the proliferation of endometrial stromal cells by inhibition of TRPV2. mechanistic or pharmacological PubMed 35714693
  145. 145
    Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. mechanistic or pharmacological PubMed 21726418
  146. 146
    An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. mechanistic or pharmacological PubMed 34500785
  147. 147
    Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. mechanistic or pharmacological PubMed 30074247
  148. 148
    Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. mechanistic or pharmacological PubMed 33446817
  149. 149
    Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models. mechanistic or pharmacological PubMed 36559009
  150. 150
    Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments. mechanistic or pharmacological PubMed 40525419
  151. 151
    Cannabivarin and tetrahydrocannabivarin modulate nociception via vanilloid channels and cannabinoid-like receptors in Caenorhabditis elegans. mechanistic or pharmacological PubMed 41135090
  152. 152
    Crystal structures of agonist-bound human cannabinoid receptor CB1. mechanistic or pharmacological PubMed 40866700
  153. 153
    Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. mechanistic or pharmacological PubMed 35489334
  154. 154
    Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism. mechanistic or pharmacological PubMed 38101408
  155. 155
    A cryptic pocket in CB1 drives peripheral and functional selectivity. mechanistic or pharmacological PubMed 40044849
  156. 156
    Assay of CB1 Receptor Binding. mechanistic or pharmacological PubMed 27245890
  157. 157
    Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1. mechanistic or pharmacological PubMed 38830102
  158. 158
    Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. mechanistic or pharmacological PubMed 22343625
  159. 159
    CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity. mechanistic or pharmacological PubMed 38675703
  160. 160
    Allosteric modulation of the cannabinoid CB1 receptor. mechanistic or pharmacological PubMed 16113085
  161. 161
    Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation. mechanistic or pharmacological PubMed 31968549
  162. 162
    Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. mechanistic or pharmacological PubMed 28103441
  163. 163
    The future of type 1 cannabinoid receptor allosteric ligands. mechanistic or pharmacological PubMed 29355038
  164. 164
    Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). mechanistic or pharmacological PubMed 25162172
  165. 165
    Crystal structures of agonist-bound human cannabinoid receptor CB1. mechanistic or pharmacological PubMed 28678776
  166. 166
    Structural mechanism of CB1R binding to peripheral and biased inverse agonists. mechanistic or pharmacological PubMed 39695122
  167. 167
    Targeting mechanosensitive cannabinoid receptor 1 with isoflavone prodrugs attenuates atherosclerotic endothelial dysfunction. mechanistic or pharmacological PubMed 41559687
  168. 168
    Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist. mechanistic or pharmacological PubMed 40521518
  169. 169
    CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. mechanistic or pharmacological PubMed 17895407
  170. 170
    Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism. mechanistic or pharmacological PubMed 36088492
  171. 171
    Role of the cannabinoid CB1 receptor in methamphetamine-induced social and recognition memory impairment. mechanistic or pharmacological PubMed 35429587
  172. 172
    Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models. mechanistic or pharmacological PubMed 40855505
  173. 173
    Adipocyte cannabinoid CB1 receptor deficiency alleviates high fat diet-induced memory deficit, depressive-like behavior, neuroinflammation and impairment in adult neurogenesis. mechanistic or pharmacological PubMed 31491589
  174. 174
    A cannabinoid link between mitochondria and memory. mechanistic or pharmacological PubMed 27828947
  175. 175
    Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome. mechanistic or pharmacological PubMed 39300547
  176. 176
    Cross state-dependent memory retrieval between cannabinoid CB1 and serotonergic 5-HT1A receptor agonists in the mouse dorsal hippocampus. mechanistic or pharmacological PubMed 35595026
  177. 177
    Adenosine receptors are the on-and-off switch of astrocytic cannabinoid type 1 (CB1) receptor effect upon synaptic plasticity in the medial prefrontal cortex. mechanistic or pharmacological PubMed 38482984
  178. 178
    Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice. mechanistic or pharmacological PubMed 36613469
  179. 179
    A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay. mechanistic or pharmacological PubMed 40271066
  180. 180
    CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency. mechanistic or pharmacological PubMed 26124120
  181. 181
    Crystal Structure of the Human Cannabinoid Receptor CB2. mechanistic or pharmacological PubMed 30639103
  182. 182
    Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex. mechanistic or pharmacological PubMed 32004460
  183. 183
    Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. mechanistic or pharmacological PubMed 28220706
  184. 184
    A Cannabinoid Type 2 (CB2) Receptor Agonist Augments NOS-Dependent Responses of Cerebral Arterioles During Type 1 Diabetes. mechanistic or pharmacological PubMed 36889269
  185. 185
    CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder. mechanistic or pharmacological PubMed 33749323
  186. 186
    CB2 cannabinoid receptor-mediated peripheral antinociception. mechanistic or pharmacological PubMed 11514083
  187. 187
    CB2 cannabinoid receptor mediation of antinociception. mechanistic or pharmacological PubMed 16563625
  188. 188
    The Cannabinoid-2 receptor agonist, 1-phenylisatin, protects against cisplatin-induced nephrotoxicity in mice. mechanistic or pharmacological PubMed 36058263
  189. 189
    Cannabinoid Receptor Type 2 Agonist Reduces Morphine Tolerance via Mitogen Activated Protein Kinase Phosphatase Induction and Mitogen Activated Protein Kinase Dephosphorylation. mechanistic or pharmacological PubMed 34774714
  190. 190
    The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats. mechanistic or pharmacological PubMed 27608434
  191. 191
    The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. mechanistic or pharmacological PubMed 20849866
  192. 192
    Structural basis of selective cannabinoid CB2 receptor activation. mechanistic or pharmacological PubMed 36922494
  193. 193
    Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease. mechanistic or pharmacological PubMed 38662453
  194. 194
    Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation. mechanistic or pharmacological PubMed 39173999
  195. 195
    Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation. mechanistic or pharmacological PubMed 36475439
  196. 196
    Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice. mechanistic or pharmacological PubMed 37061199
  197. 197
    The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. mechanistic or pharmacological PubMed 18615177
  198. 198
    Cannabinoid receptor 2 activation mitigates lipopolysaccharide-induced neuroinflammation and sickness behavior in mice. mechanistic or pharmacological PubMed 30666359
  199. 199
    Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain. mechanistic or pharmacological PubMed 37286073
  200. 200
    Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2. mechanistic or pharmacological PubMed 26824325
  201. 201
    CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. mechanistic or pharmacological PubMed 23960212
  202. 202
    Enantiomeric Agonists of the Type 2 Cannabinoid Receptor Reduce Retinal Damage during Proliferative Vitreoretinopathy and Inhibit Hyperactive Microglia In Vitro. mechanistic or pharmacological PubMed 38751621
  203. 203
    Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. mechanistic or pharmacological PubMed 12823482
  204. 204
    Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats. mechanistic or pharmacological PubMed 30414958
  205. 205
    Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation. mechanistic or pharmacological PubMed 36583304
  206. 206
    A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling. mechanistic or pharmacological PubMed 41875735
  207. 207
    Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease. mechanistic or pharmacological PubMed 40332343
  208. 208
    CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy. mechanistic or pharmacological PubMed 41383775
  209. 209
    Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases. mechanistic or pharmacological PubMed 40791361
  210. 210
    Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. mechanistic or pharmacological PubMed 16086683
  211. 211
    Cannabinoid receptor 2 affect the inflammatory response in periodontitis by regulating macrophage M1/M2 polarization. mechanistic or pharmacological PubMed 41310604
  212. 212
    The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. mechanistic or pharmacological PubMed 18247131
  213. 213
    Cannabinoid receptor type 2 agonist GP1a attenuates macrophage activation induced by M. bovis-BCG by inhibiting NF-κB signaling. mechanistic or pharmacological PubMed 39538989
  214. 214
    Cannabinoid receptor 2 activating antibodies: A promising therapeutic strategy for macrophage-driven fibro-inflammatory diseases. mechanistic or pharmacological PubMed 41740200
  215. 215
    The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. mechanistic or pharmacological PubMed 18757503
  216. 216
    The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. mechanistic or pharmacological PubMed 17704827
  217. 217
    The orphan receptor GPR55 is a novel cannabinoid receptor. mechanistic or pharmacological PubMed 17876302
  218. 218
    Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors. mechanistic or pharmacological PubMed 36016551
  219. 219
    Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18. mechanistic or pharmacological PubMed 32365486
  220. 220
    Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18. mechanistic or pharmacological PubMed 29902723
  221. 221
    Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. mechanistic or pharmacological PubMed 24762058
  222. 222
    Structural insights into the activation of G protein-coupled receptor 119 by the agonist GSK1292263 and ligands selectivity among novel cannabinoid receptors. mechanistic or pharmacological PubMed 40562148
  223. 223
    GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine. mechanistic or pharmacological PubMed 27018161
  224. 224
    Protective Effect of N-Arachidonoyl Glycine-GPR18 Signaling after Excitotoxical Lesion in Murine Organotypic Hippocampal Slice Cultures. mechanistic or pharmacological PubMed 30871175
  225. 225
    N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. mechanistic or pharmacological PubMed 20346144
  226. 226
    siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migration. mechanistic or pharmacological PubMed 22834922
  227. 227
    Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. mechanistic or pharmacological PubMed 21595653
  228. 228
    A GPR18-based signalling system regulates IOP in murine eye. mechanistic or pharmacological PubMed 23461720
  229. 229
    The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure. mechanistic or pharmacological PubMed 24431468
  230. 230
    Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature. mechanistic or pharmacological PubMed 24751709
  231. 231
    Regulation of GPR119 receptor activity with endocannabinoid-like lipids. mechanistic or pharmacological PubMed 23074242
  232. 232
    Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. mechanistic or pharmacological PubMed 37199723
  233. 233
    The TRPV1 channel regulates glucose metabolism. mechanistic or pharmacological PubMed 31408376
  234. 234
    Tyrosine phosphorylation and palmitoylation of TRPV2 ion channel tune microglial beta-amyloid peptide phagocytosis. mechanistic or pharmacological PubMed 39227967
  235. 235
    Cannabinoid non-cannabidiol site modulation of TRPV2 structure and function. mechanistic or pharmacological PubMed 36470868
  236. 236
    Molecular mechanism of TRPV2 channel modulation by cannabidiol. mechanistic or pharmacological PubMed 31566564
  237. 237
    TRPV2, a novel player in the human ovary and human granulosa cells. mechanistic or pharmacological PubMed 37610352
  238. 238
    The Protective Effect of CBD in a Model of In Vitro Ischemia May Be Mediated by Agonism on TRPV2 Channel and Microglia Activation. mechanistic or pharmacological PubMed 36292998
  239. 239
    The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib. mechanistic or pharmacological PubMed 34971020
  240. 240
    Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. mechanistic or pharmacological PubMed 36747846
  241. 241
    Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. mechanistic or pharmacological PubMed 23079154
  242. 242
    Cannabidiol Enhances Microglial Beta-Amyloid Peptide Phagocytosis and Clearance via Vanilloid Family Type 2 Channel Activation. mechanistic or pharmacological PubMed 35628181
  243. 243
    Human podocytes express functional thermosensitive TRPV channels. mechanistic or pharmacological PubMed 28945920
  244. 244
    Exploring Cannabidiol-TRPV3 Mediated Biological Activities-Findings From Molecular Docking, Simulation and Proteins Network Interactions. mechanistic or pharmacological PubMed 40025806
  245. 245
    The Impact of a Quinone Scaffold on Thermo-TRPs Modulation by Dimethylheptyl Phytocannabinoids. mechanistic or pharmacological PubMed 40141324
  246. 246
    Modification of TRPV4 activity by acetaminophen. mechanistic or pharmacological PubMed 32051870
  247. 247
    Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region. mechanistic or pharmacological PubMed 38750093
  248. 248
    Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy. mechanistic or pharmacological PubMed 41802611
  249. 249
    Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol. mechanistic or pharmacological PubMed 26294342
  250. 250
    Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. mechanistic or pharmacological PubMed 25061872
  251. 251
    Identification of the TRPA1 cannabinoid-binding site. mechanistic or pharmacological PubMed 39368566
  252. 252
    Affinin, Isolated from Heliopsis longipes, Induces an Antihypertensive Effect That Involves CB1 Cannabinoid Receptors and TRPA1 and TRPV1 Channel Activation. mechanistic or pharmacological PubMed 38219731
  253. 253
    Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. mechanistic or pharmacological PubMed 25065940
  254. 254
    Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons. mechanistic or pharmacological PubMed 21645531
  255. 255
    Cannabidiol activation of vagal afferent neurons requires TRPA1. mechanistic or pharmacological PubMed 32965166
  256. 256
    Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. mechanistic or pharmacological PubMed 32873774
  257. 257
    Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannabigerol-Rich Cannabis sativa L. Chemotype IV. mechanistic or pharmacological PubMed 38408345
  258. 258
    Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. mechanistic or pharmacological PubMed 18354058
  259. 259
    TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice. mechanistic or pharmacological PubMed 39684707
  260. 260
    Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. mechanistic or pharmacological PubMed 17428469
  261. 261
    Iodine-mediated cyclization of cannabigerol (CBG) expands the cannabinoid biological and chemical space. mechanistic or pharmacological PubMed 30077611
  262. 262
    The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells. mechanistic or pharmacological PubMed 34126378
  263. 263
    Endocannabinoids. mechanistic or pharmacological PubMed 35038882
  264. 264
    Cannabinoid CB1 receptors regulate salivation. mechanistic or pharmacological PubMed 35986066
  265. 265
    Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. mechanistic or pharmacological PubMed 11470906
  266. 266
    Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. mechanistic or pharmacological PubMed 39612328
  267. 267
    Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. mechanistic or pharmacological PubMed 24768821
  268. 268
    2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice. mechanistic or pharmacological PubMed 36125319
  269. 269
    The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. mechanistic or pharmacological PubMed 33450278
  270. 270
    Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b. mechanistic or pharmacological PubMed 36481187
  271. 271
    Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. mechanistic or pharmacological PubMed 17449181
  272. 272
    The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice. mechanistic or pharmacological PubMed 29936173
  273. 273
    GPR119 Is a Potent Regulator of Human Sebocyte Biology. mechanistic or pharmacological PubMed 32142797
  274. 274
    Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy. mechanistic or pharmacological PubMed 30702457
  275. 275
    Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation. mechanistic or pharmacological PubMed 40563990
  276. 276
    Probiotics and palmitoylethanolamide (PEA) for osteoarthritic pain: individual effects in a multiple baseline design study. mechanistic or pharmacological PubMed 41709243
  277. 277
    Protective effect of palmitoylethanolamide in a rat model of cystitis. mechanistic or pharmacological PubMed 25463999
  278. 278
    Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. mechanistic or pharmacological PubMed 27720681
  279. 279
    Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. mechanistic or pharmacological PubMed 28336953
  280. 280
    The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. mechanistic or pharmacological PubMed 9344854
  281. 281
    Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. mechanistic or pharmacological PubMed 10221757
  282. 282
    Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. mechanistic or pharmacological PubMed 8900284
  283. 283
    The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist. mechanistic or pharmacological PubMed 10574567
  284. 284
    TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. mechanistic or pharmacological PubMed 15245490
  285. 285
    Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. mechanistic or pharmacological PubMed 17459108
  286. 286
    The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. mechanistic or pharmacological PubMed 24644287
  287. 287
    Endovanilloids are potential activators of the trigeminovascular nocisensor complex. mechanistic or pharmacological PubMed 27189587
  288. 288
    Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population. mechanistic or pharmacological PubMed 20354008
  289. 289
    Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. mechanistic or pharmacological PubMed 15289293
  290. 290
    Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. mechanistic or pharmacological PubMed 15006899
  291. 291
    A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells. mechanistic or pharmacological PubMed 25995819
  292. 292
    N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1. mechanistic or pharmacological PubMed 28701511
  293. 293
    N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. mechanistic or pharmacological PubMed 16760924
  294. 294
    Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel. mechanistic or pharmacological PubMed 33568652
  295. 295
    Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor. mechanistic or pharmacological PubMed 17984664
  296. 296
    2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. mechanistic or pharmacological PubMed 11259648
  297. 297
    Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. mechanistic or pharmacological PubMed 17698254
  298. 298
    Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. mechanistic or pharmacological PubMed 16639008
  299. 299
    Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. mechanistic or pharmacological PubMed 12787057
  300. 300
    The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. mechanistic or pharmacological PubMed 15901805
  301. 301
    Activation of CB1R alleviates central sensitization by regulating HCN2-pNR2B signaling in a chronic migraine rat model. mechanistic or pharmacological PubMed 37085778
  302. 302
    Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor. mechanistic or pharmacological PubMed 15148262
  303. 303
    Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats. mechanistic or pharmacological PubMed 22309979
  304. 304
    Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. mechanistic or pharmacological PubMed 12356827
  305. 305
    Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. mechanistic or pharmacological PubMed 18806815
  306. 306
    Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. mechanistic or pharmacological PubMed 12023533
  307. 307
    The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. mechanistic or pharmacological PubMed 22454039
  308. 308
    Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria. mechanistic or pharmacological PubMed 32696508
  309. 309
    Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. mechanistic or pharmacological PubMed 15233865
  310. 310
    Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B. mechanistic or pharmacological PubMed 29958841
  311. 311
    Mechanism of platelet activation induced by endocannabinoids in blood and plasma. mechanistic or pharmacological PubMed 23789792
  312. 312
    (Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells. mechanistic or pharmacological PubMed 19255745
  313. 313
    N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. mechanistic or pharmacological PubMed 27809877
  314. 314
    N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation. mechanistic or pharmacological PubMed 23570577
  315. 315
    Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function. mechanistic or pharmacological PubMed 27759003
  316. 316
    The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study. mechanistic or pharmacological PubMed 35203453
  317. 317
    Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine. mechanistic or pharmacological PubMed 21573043
  318. 318
    Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease. mechanistic or pharmacological PubMed 26707833
  319. 319
    Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. mechanistic or pharmacological PubMed 16081411
  320. 320
    Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. mechanistic or pharmacological PubMed 17574742
  321. 321
    Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. mechanistic or pharmacological PubMed 12010121
  322. 322
    High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. mechanistic or pharmacological PubMed 22125609
  323. 323
    Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. mechanistic or pharmacological PubMed 23707281
  324. 324
    High levels of endogenous lipid mediators (N-acylethanolamines) in women with chronic widespread pain during acute tissue trauma. mechanistic or pharmacological PubMed 27531672
  325. 325
    Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. mechanistic or pharmacological PubMed 16154384